Skip to content

Study Details

DNL310: A Study Drug for Children and Adolescents with Hunter Syndrome

(IRB#: IRB_00157640)

Hunter syndrome is a disease that may cause delays in cognitive (part of the brain) development and disruptive and impaired behaviors in children and adolescents. DNL310 is a study drug for children and adolescents with Hunter Syndrome. Research is needed to learn the safety and effectiveness of DNL310. The information we gain may aid future patients.


  • All genders
  • All Ages
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: All Ages

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 2 to 5 years old who have Neuronopathic Hunter syndrome OR
  • Ages 6 to 16 years old who have Non-neuronopathic Hunter syndrome
  • Be on maintenance of enzyme replacement therapy (ERT) and taking 4 months of Elaprase medication for Hunter syndrome
  • Childbearing-age participants must use specific birth control
  • Attend in person at the University of Utah

Exclusion Criteria

  • Unstable medical condition
  • History of cancer
  • Significant diagnosis of the central nervous system (brain and spinal cord) trauma or disorder
  • Serious or life-threatening reactions to any part of the study drug that cannot be controlled
  • Pregnant

Will I be paid for my time?


For more information contact:

Carrie Bailey


IRB#: IRB_00157640

PI: David Viskochil

Department: PEDIATRICS

Approval Date: 2023-07-26 06:00:00

Specialties: Pediatric Genetics

Last Updated: 6/8/23